Agilent Technologies Teams with University of Liverpool's Centre for Genomic Research
News Aug 08, 2012
The CGR has been conducting research at the leading edge of genomic technologies and data analysis in Liverpool, England, for over a decade. With a diverse portfolio of projects including metagenomics, plant and animal studies, cancer genomics and human genetics, the CGR is constantly exploring new technologies and making innovative approaches and applications available to researchers investigating fundamental and applied biology.
SureSelect has been shown to greatly increase the speed and efficiency of next-generation sequencing by enabling researchers to focus experiments on genomic regions of interest rather than sequencing the entire genome. Since it was introduced in 2009, SureSelect has been instrumental in more than 250 published studies covering research into a wide range of heritable disorders and complex diseases.
"We have relied on SureSelect in our research efforts to produce consistent results that we and our collaborators can be confident in," said professor Andy Cossins, head of the Institute of Integrative Biology and co-director of the Centre for Genomic Research. "Achieving certified status is an important step for the CGR and will allow us to expand our sequencing leadership."
"The CGR is a highly regarded collaborator in the sequencing community, and we're pleased that they are now enabling more researchers across the UK to access the market-leading platform for target enrichment," said Kathleen Shelton, senior director of Genomics Marketing at Agilent. "Their certification is a great complement for our SureSelect portfolio and will be a great benefit to collaborators."
To be certified, the CGR participated in comprehensive on-site training and then passed a rigorous set of requirements to demonstrate expertise and skill.
The SureSelect portfolio now includes more than 21 products, and many more are in development. SureSelect is compatible with major sequencing platforms such as Illumina, SOLiD and 454. Users of Agilent's eArray design tool can improve the efficiency of their research by easily designing custom products to target any genomic regions of interest. SureSelect also allows customization of catalog kits with the addition of custom content.
CRISPR Used to Prevent Development of Angiogenesis of the RetinaNews
Powerful new technology may lead to novel therapies to prevent vision loss, blindness in those with diseases of the retina.READ MORE
Could This Be a "Silver Bullet" for Preventing and Treating Colon Cancer?News
A team of scientists targeted the gene CtBP with a drug known as HIPP (2-hydroxy-imino phenylpyruvic acid) and were able to reduce the development of pre-cancerous polyps by half.READ MORE
FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic LeukemiaNews
TheFDA has changed its accelerated approval of blinatumomab (Blincyto®) for some patients with acute lymphoblastic leukemia to a full approval and expanded the approved indications for its use.READ MORE
Comments | 0 ADD COMMENT
11th International Conference on Cancer Stem Cells
Jun 11 - Jun 13, 2018